Acurx Pharmaceuticals, Inc. 8-K

What Happened

• Acurx Pharmaceuticals (ACXP) announced on April 15–16, 2026 that it entered a Securities Purchase Agreement to raise approximately $2.5 million (gross) through a registered direct offering and a concurrent private placement.
• The offering includes 816,068 shares of common stock at $3.03 per share and pre‑funded warrants to purchase up to 9,017 shares at $3.029 per pre‑funded warrant. In the private placement, the company issued Series H warrants to purchase up to 1,650,170 shares at an exercise price of $2.78 per share (immediately exercisable; expiration tied to a registration statement timing provision).
• Acurx engaged H.C. Wainwright & Co., LLC as exclusive placement agent and issued a pricing press release on April 16, 2026 announcing the transaction.

Key Details

• Aggregate gross proceeds: ~ $2.5 million (before placement agent fees and expenses). Company will use net proceeds for working capital and general corporate purposes.
• Security counts and prices: 816,068 common shares at $3.03; pre‑funded warrants for 9,017 shares at $3.029; Series H warrants for up to 1,650,170 shares with $2.78 exercise price.
• Placement agent fees/expenses: 6.0% cash fee of gross proceeds, plus up to $50,000 for legal fees and $15,950 for clearing expenses to H.C. Wainwright.
• Ownership limits: Holders are blocked from exercising warrants to the extent that doing so would raise their ownership above 4.99% (or, if elected at issuance, 9.99%) without advance notice (61 days to increase from 4.99% to 9.99%).
• Lock-up and other issuance limits: Company agreed to a 15‑day lock‑up on issuing/selling common stock or equivalents and to avoid variable rate transactions for one year after closing, though it may use an ATM facility with Wainwright or enter an equity line after the lock‑up.

Why It Matters

• This transaction provides Acurx with immediate capital (roughly $2.5M gross) to support working capital and ongoing corporate needs, which can extend runway but will dilute existing shareholders when shares/warrants are issued or exercised.
• The Series H and pre‑funded warrants, once exercised, could meaningfully increase share count; exercise restrictions and the company’s commitment to register resale of shares underlying the Series H warrants are important to monitor for future dilution and liquidity.
• Warrants are not listed and may have limited liquidity until/if registered shares become tradable; placement agent fees reduce net proceeds. Investors should watch subsequent filings for the closing, any S‑1 registration effectiveness for warrant resale, and changes in share count.